A double blinded, randomized, dose escalating efficacy and safety study of implitapide at daily doses o 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg compared with placebo in patients with heterozygous familial hypercholesterolemia (HeFH) on